Price movement over the last 24 hours
Alcon AG vs Datadog Inc — how do they compare? Alcon AG trades at $66.97 (market cap $32.69B), while Datadog Inc trades at $257 (market cap $91.41B). The key difference: Datadog Inc is far larger — about 2.8× Alcon AG's market cap, and Alcon AG pays a 0.54% dividend while Datadog Inc pays none. Which is the better fit depends on your goals.
| ALC | DDOG | |
|---|---|---|
Market Cap | $32.69B | $91.41B |
Sector | Health | Technology |
52-Week High | $92.22 | $277.49 |
52-Week Low | $62.02 | $102.62 |
Enterprise Value | $36.28B | $87.94B |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Datadog (DDOG) trades at $256.81, down 1.36% over the past day but maintains a bullish technical outlook with strong moving average signals. The company reported revenue of $3.43B in 2025 with consistent earnings beats, though net income margin compressed to 3.69%. Recent acquisition of Adaptive ML aims to bolster AI research capabilities, while analyst sentiment remains overwhelmingly positive with 83% buy ratings.
DDOG presents growth potential through cloud infrastructure demand and AI integration, but faces risks from high valuation multiples (P/E 654.79) and negative cash flow trends. Competition in observability software and execution challenges could pressure margins, though institutional support provides stability. The stock's trajectory hinges on sustaining revenue growth while improving profitability.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →